2. Metabolic Enzyme/Protease Protein Tyrosine Kinase/RTK Epigenetics Cell Cycle/DNA Damage
  3. Glycosidase c-Kit MMP VEGFR Aurora Kinase
  4. Quercimeritrin

Quercimeritrin  (Synonyms: Quercetin-7-O-β-D-glucopyranoside)

Cat. No.: HY-N0419 Purity: 99.48%
COA
SDS
Handling Instructions Technical Support

Quercimeritrin (Quercetin-7-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor (with an IC50 of 79.88 μM against the Saccharomyces cerevisiae enzyme) and a P-gp substrate, with anti-angiogenic and antioxidant activities. Quercimeritrin does not cross the blood-brain barrier and does not inhibit cytochrome P450 enzymes. Quercimeritrin precisely binds to and inhibits the active sites of c-Kit, MMP-2, Aurora-A kinases and α-glucosidase, thereby disrupting target functions. Quercimeritrin effectively regulates postprandial blood glucose and also exhibits significant anti-angiogenic activity, which inhibits endothelial cell proliferation and microvascular growth. Quercimeritrin can be used in the research of diabetes and breast cancer.

For research use only. We do not sell to patients.

Quercimeritrin

Quercimeritrin Chemical Structure

CAS No. : 491-50-9

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Quercimeritrin:

Quercimeritrin Related Antibodies

Top Publications Citing Use of Products

View All MMP Isoform Specific Products:

View All Isoforms
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

View All Aurora Kinase Isoform Specific Products:

View All Isoforms
Aurora Kinase Aurora A Aurora B Aurora C

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Quercimeritrin (Quercetin-7-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor (with an IC50 of 79.88 μM against the Saccharomyces cerevisiae enzyme) and a P-gp substrate, with anti-angiogenic and antioxidant activities. Quercimeritrin does not cross the blood-brain barrier and does not inhibit cytochrome P450 enzymes. Quercimeritrin precisely binds to and inhibits the active sites of c-Kit, MMP-2, Aurora-A kinases and α-glucosidase, thereby disrupting target functions. Quercimeritrin effectively regulates postprandial blood glucose and also exhibits significant anti-angiogenic activity, which inhibits endothelial cell proliferation and microvascular growth. Quercimeritrin can be used in the research of diabetes and breast cancer[1][2][3].

IC50 & Target

VEGFR2

 

MMP-2

 

MMP-9

 

Cellular Effect
Cell Line Type Value Description References
KB ED50
28 μg/mL
Compound: NSC-115917
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
[PMID: 469554]
In Vitro

Quercimeritrin has a high absorption rate in the human intestine, cannot cross the blood-brain barrier, and does not inhibit major CYPs. It is a substrate of P-gp, and fails to meet one of the Ghose rules due to its low lipophilicity[1].
Quercimeritrin (3.91-500 μM; 10-20 min) potently inhibits α-glucosidase isolated from Saccharomyces cerevisiae, with an IC50 of 79.88 μM, and exhibits a concentration-dependent inhibitory effect[2].
Quercimeritrin (3.91-500 μM; 10-20 min) weakly inhibits porcine pancreas-derived α-amylase, with an IC50 value greater than 250 μM[2].
Quercimeritrin (15.6-500 μM) competitively inhibits α-glucosidase from Saccharomyces cerevisiae and α-amylase from porcine pancreas, and exhibits higher binding affinity for α-glucosidase[2].
Quercimeritrin (10-100 μM; 72 h) inhibits the proliferation of human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner, with a significant inhibitory effect observed at 100 μM[3].
Quercimeritrin (100 μM; 12 h) cannot effectively inhibit tube formation in human umbilical vein endothelial cells (HUVECs), with an inhibition rate of less than 20%[3].
Quercimeritrin (100 μM; 6 h) does not inhibit VEGF-induced HUVEC migration in Boyden chamber assays[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Quercimeritrin Related Antibodies

Cell Proliferation Assay[3]

Cell Line: Human umbilical vein endothelial cell (HUVEC)
Concentration: 10, 100 μM
Incubation Time: 72 h
Result: Suppressed HUVEC proliferation in a dose-dependent manner at 10-100 μM.
Significantly suppressed HUVEC proliferation at 100 μM.

Cell Migration Assay[3]

Cell Line: Human umbilical vein endothelial cell (HUVEC)
Concentration: 100 μM
Incubation Time: 6 h
Result: Did not suppress VEGF-induced HUVEC migration, with migrated cell numbers similar to the positive control (VEGF alone).
In Vivo

Quercimeritrin (100-200 mg/kg; oral; single dose) significantly inhibits postprandial hyperglycemia in db/db mice, with the 200 mg/kg oral dose reducing glucose AUC0-t by 24.5% and the 100 mg/kg dose reducing glucose AUC0-t by 19.0%[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: db/db mice[2]
Dosage: 100 mg/kg; 200 mg/kg
Administration: oral; single dose
Result: Reduced postprandial glucose area under the curve (AUC) by 19.0% to 43.7 mmol/(L*h) compared to the model group (100 mg/kg dose).
Reduced postprandial glucose AUC by 24.5% to 40.7 mmol/(L*h) compared to the model group (200 mg/kg dose).
Resulted in a significantly lower postprandial blood glucose level at 120 minutes than the control and acarbose groups (200 mg/kg dose).
Molecular Weight

464.38

Formula

C21H20O12
CAS No.
Appearance

Solid

Color

White to yellow

SMILES

OC1=CC=C(C(OC2=C3C(O)=CC(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C2)=C(O)C3=O)C=C1O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 33.33 mg/mL (71.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1534 mL 10.7670 mL 21.5341 mL
5 mM 0.4307 mL 2.1534 mL 4.3068 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.48%

SDS (252 KB)

COA (250 KB) HNMR (288 KB) CNMR (127 KB) RP-HPLC (285 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1534 mL 10.7670 mL 21.5341 mL 53.8352 mL
5 mM 0.4307 mL 2.1534 mL 4.3068 mL 10.7670 mL
10 mM 0.2153 mL 1.0767 mL 2.1534 mL 5.3835 mL
15 mM 0.1436 mL 0.7178 mL 1.4356 mL 3.5890 mL
20 mM 0.1077 mL 0.5384 mL 1.0767 mL 2.6918 mL
25 mM 0.0861 mL 0.4307 mL 0.8614 mL 2.1534 mL
30 mM 0.0718 mL 0.3589 mL 0.7178 mL 1.7945 mL
40 mM 0.0538 mL 0.2692 mL 0.5384 mL 1.3459 mL
50 mM 0.0431 mL 0.2153 mL 0.4307 mL 1.0767 mL
60 mM 0.0359 mL 0.1795 mL 0.3589 mL 0.8973 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Quercimeritrin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Quercimeritrin491-50-9Quercetin-7-O-β-D-glucopyranosideGlycosidasec-KitMMPVEGFRAurora KinaseSCFRCD117Matrix metalloproteinasesVascular endothelial growth factor receptorAurora-A kinaseendothelial cellP-gpα-glucosidasebreast cancerMMP-2c-Kit tyrosine kinasecytochrome P450 enzymesHUVECSaccharomyces cerevisiaeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Quercimeritrin
Cat. No.:
HY-N0419
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.